In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.27, marking a +1.15% move from the previous day. The stock's performance was ahead of the S&P 500's daily gain of 0.83%. At ...

Objective Long-term azithromycin treatment effectively prevents acute exacerbations of chronic obstructive pulmonary disease ...

See Recursion Pharmaceuticals, Inc. (RXRX) Environment, Social and Governance Ratings to help you in your stock buying decisions.

Discover real-time Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead ...

Stay up-to-date on Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) news with the latest updates, breaking headlines, news articles, and more from around the web at Nasdaq.com.